Vouliez-vous dire
arise, kevin k

Résultats de la recherche - 28 results

Immunovirological and environmental screening reveals actionable risk factors for fatal COVID-19 during post-vaccination nursing home outbreaksAbstract

Ricardo; Delforge, Marie-Luce; Vael, Carl; Berckmans, Lynsey; Selhorst, Philippe; Ariën, Kevin K.; Van Dooren, Sonia; Hinckel, Bruno; Imamura, Hideo; Janssen, Toon; Caljon, Ben; Soetens, Oriane; Piérard, ...

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factorsBackgroundMethodsResultsConclusionDataSheet_1.docx

Vanhoutte, Greetje; Peeters, Bart; Raats, Silke; Massen, Isolde Van der; De Keersmaecker, Sven; Debie, Yana; Huizing, Manon; Pannus, Pieter; Neven, Kristof Y.; Ariën, Kevin K.; Martens, Geert A.; Bulcke, Marc ...

Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients.

Lemy, Anne; Maria Goossens; I Desombere; Michiels, Johan; Vandevenne, Marylène; Heyndrickx, Leo; Ariën, Kevin K; Matagne, André; Ackerman, Margaret E; Le Moine, Alain; Marchant, Arnaud Source: Am ...

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults.

Verbrugghe, Mathieu; Van Loon, Nele; Dierick, Katelijne; Matagne, André; Desombere, Isabelle; Ariën, Kevin K; Marchant, Arnaud; Maria Goossens Source: Vaccine, Volume 41, Issue 17 (2023) Keywords: Adult ...

Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults

Verbrugghe, Mathieu; Van Loon, Nele; Dierick, Katelijne; Matagne, André; I Desombere; Ariën, Kevin K.; Marchant, Arnaud; Maria Goossens Source: Vaccine, Volume 41, Issue 17 (2023) Health Topics:  Health and ...

Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): A single blind, randomized, non-inferiority trial

I Desombere; Kevin K. Ariën; Maria Goossens Source: PLOS Global Public Health, Volume 2, Issue 12 (2022) Keywords: COVID-19; fractional dose; reduced dose; mRNA vaccination; non-inferiority; SARS-CoV-2 Abstract: ...

Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.

Lisa Verheggen; Debbie Le Blon; Bart Peeters; Maria Goossens; Pieter Pannus; Ariën, Kevin K; Sébastien Anguille; Annelies Janssens; Hans Prenen; Evelien L J Smits; Christof Vulsteke; Eva Lion; Peeters, ...

Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients.

Publication Type: Peer reviewed scientific article Authors: Frédéric Baron; Lorenzo Canti; Ariën, Kevin K; Delphine Kemlin; I Desombere; Margaux Gerbaux; Pieter Pannus; Yves Beguin; Arnaud Marchant; ...

Predictive model for BNT162b2 vaccine response in cancer patients based on blood cytokines and growth factors.

Vanhoutte; Bart Peeters; Silke Raats; Isolde Van der Massen; Sven De Keersmaecker; Yana Debie; Manon Huizing; Pieter Pannus; Kristof Y Neven; Ariën, Kevin K; Geert A Martens; Marc Van den Bulcke; Ella Roelant; ...

QR code

QR code for this page URL